# Study of Efficacy and Safety of MEXIDOL® in Ischemic Stroke Therapy

Study · id `cardio:ct-nct02793687` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02793687](<https://clinicaltrials.gov/study/NCT02793687>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02793687

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.

## Technical summary

Registry record NCT02793687. Randomized; double masking; primary purpose treatment. Start 2015-03-06 (actual); primary completion 2016-05-27 (actual). Results posted on 2025-02-24.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 150 participants (enrolled count; ClinicalTrials.gov record NCT02793687, source copy `cardio:ctgov-nct02793687-2025-02-24`, retrieved 2026-10-26)
- Started: 2015-03-06 (actual) (ClinicalTrials.gov record NCT02793687, source copy `cardio:ctgov-nct02793687-2025-02-24`, retrieved 2026-10-26)
- Primary completion: 2016-05-27 (actual) (ClinicalTrials.gov record NCT02793687, source copy `cardio:ctgov-nct02793687-2025-02-24`, retrieved 2026-10-26)
- Completion: 2016-05-27 (actual) (ClinicalTrials.gov record NCT02793687, source copy `cardio:ctgov-nct02793687-2025-02-24`, retrieved 2026-10-26)
- Results first posted: 2025-02-24 (ClinicalTrials.gov record NCT02793687, source copy `cardio:ctgov-nct02793687-2025-02-24`, retrieved 2026-10-26)
- Countries: Russia (ClinicalTrials.gov record NCT02793687, source copy `cardio:ctgov-nct02793687-2025-02-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02793687-2025-02-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of Efficacy and Safety of MEXIDOL® in Ischemic Stroke Therapy
- Acronym: EPICA
- Condition: Ischemic Stroke
- Intervention (Drug): Mexidol
- Intervention (Other): Placebo
- Lead sponsor: Pharmasoft
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Pharmasoft (`cardio:org-pharmasoft`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: \[Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA)\] (`cardio:pubmed-28665371`)
- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: \[Efficacy and safety of mexidol across age groups in the acute and early recovery stages of hemispheric ischemic stroke (results of additional sub-analysis of a randomized double blind multicenter placebo-controlled study, in parallel groups trial EPICA)\] (`cardio:pubmed-33016677`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 22b97365421a59b5a5752b76a566440c211bd759931b9059955979f432997e3d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
